Recent progress in LyP-1-based strategies for targeted imaging and therapy.

However, CREKA-labeled Abraxane did not cause a highly significant inhibition in tumor volume compared to that of untargeted Abraxane, suggesting a superior efficiency in delivering Abraxane into tumors using LyP-1 as a targeting ligand instead of CREKA (Karmali et al., 2009 ).

also in 132,142 other papers